Fed. Circ. Ruling May Reshape Hatch-Waxman Litigation Map

By Ryan Davis (November 17, 2020, 8:40 PM EST) -- Patent litigation over generic drugs, which has long been concentrated in Delaware and New Jersey, may spread out to more states across the country as a result of a recent Federal Circuit ruling, potentially making disputes more complicated, attorneys say.

In a decision earlier this month, the appeals court held that under the U.S. Supreme Court's 2017 TC Heartland ruling on venue for patent cases, branded drug companies must file suits under the Hatch-Waxman Act either where a generics maker is incorporated or where it performed actions related to its application to market a generic drug.

The holding, which rejected an...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!